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Abstract: Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of 25 
death worldwide. Low-density lipoprotein cholesterol (LDL-C) is the primary cause of 26 
ASCVD and reducing LDL-C levels with statin therapy significantly reduces ASCVD risk; 27 
however, significant residual risk remains. Two monoclonal antibodies (mAbs), alirocumab 28 
and evolocumab, that target proprotein convertase subtilisin/kexin-type 9 (PCSK9), reduce 29 
LDL-C levels by up to 60% when used in combination with statins and significantly reduce 30 
the risk of recurrent ASCVD events in both stable secondary prevention and acute 31 
coronary syndrome populations. Pre-specified analyses of recent randomized controlled 32 
trials have shed light on how best to prioritize these therapies to maximize their value in 33 
select high risk groups. These data have also informed recent clinical practice guidelines 34 
and scientific statements resulting in an expanded role for PCSK9-mAbs compared to 35 
previous guidelines, albeit there are notable differences between these recommendations. 36 
Ongoing research is exploring the long-term safety of PCSK9-mAbs and their role in the 37 
acute setting as well as patients without prior myocardial infarction or stroke. Novel 38 
therapies that inhibit PCSK9 synthesis via small interfering RNA, such as inclisiran, are 39 
also in development and may reduce LDL-C levels similar to PCSK9-mAbs but with less 40 
frequent administration. Nonetheless, the PCSK9-mAbs are a breakthrough therapy and 41 
warrant consideration in very-high risk patients who are most likely to benefit. Such a 42 
personalized approach can help to ensure cost-effectiveness and maximize their value. 43 
 44 







Atherosclerotic cardiovascular disease (ASCVD) continues to be the leading cause 51 
of death worldwide.1 In the United States (US), the Center for Disease Control and 52 
Prevention (CDC) reports cardiovascular mortality rates are actually increasing despite 53 
decades of decline.2 The principal factor in the development and progression of ASCVD is 54 
low-density lipoprotein cholesterol (LDL-C).3 Thus, reducing LDL-C levels through lifestyle 55 
modification and lipid-lowering therapies are effective means of reducing ASCVD risk.4 56 
Statins are the cornerstone lipid-lowering therapy in ASCVD prevention as they have been 57 
shown to not only significantly reduce LDL-C levels but also ASCVD events and 58 
cardiovascular (CV) mortality, across a wide range of populations.3 Despite statin therapy, 59 
residual ASCVD risk remains, especially in select high risk groups with additional risk-60 
enhancing factors. While there are numerous drivers of residual CV risk, one approach to 61 
addressing it focuses on further reduction of LDL-C levels beyond what is achievable with 62 
maximally tolerated statin therapy alone. 63 
In 2015, the US Food and Drug Administration (FDA) approved two fully human 64 
therapeutic monoclonal antibodies (mAbs), alirocumab and evolocumab, for use in 65 
combination with statin therapy to lower LDL-C levels. Alirocumab and evolocumab inhibit 66 
proprotein convertase subtilisin/kexin-type 9 (PCSK9), a protein primarily expressed in 67 
hepatocytes, but also found in endothelial and smooth muscle cells, kidney mesenchymal 68 
cells, intestinal ileum, embryonic brain telencephalon neurons, and colon epithelia.5 From a 69 
physiological perspective, PCSK9 binds to LDL receptors on the hepatocyte and facilitates 70 
the intracellular degradation and compartmentalization of LDL receptors resulting in 71 
decreased availability of LDL receptors and increased circulation of LDL-C in the plasma. 72 
Because PCSK9 targets highly specific proteins, such as LDL receptors, it is an ideal 73 
therapeutic target.6 74 
 4 
The mechanism by which PCSK9-mAbs reduce LDL-C levels involves the binding 75 
of the mAb to circulating PCSK9, which disrupts the binding of PCSK9 to LDL receptors on 76 
the hepatocyte surface (Figure 1). Under normal physiological circumstances, the lifespan 77 
of LDL receptors is approximately 20 hours, and each recycles to the hepatocyte cell 78 
surface for several hundred rounds of receptor-mediated endocytosis.7 Thus, PCSK9-79 
mAbs interfere with the normal LDL receptor recycling loop and increases the recycling of 80 
LDL receptors to facilitate the removal of LDL-C from the plasma resulting in lower LDL-C 81 
levels. Both PCSK-mAbs have demonstrated high affinity and specificity for PSCK9.8,9 82 
They are each formulated as subcutaneous injections and self-administered either bi-83 
weekly or once-monthly, depending on patient preference. To date, both alirocumab and 84 
evolocumab are generally well tolerated with injection site reactions being the most 85 
frequently reported adverse effect.10 86 
Since FDA approval in 2015, two randomized, placebo-controlled trials have 87 
demonstrated that both alirocumab and evolocumab significantly reduce LDL-C levels (up 88 
to 60%), and more importantly, reduce the risk of recurrent CV events in patients receiving 89 
maximally tolerated statin therapy with prior myocardial infarction (MI) or ischemic 90 
stroke.11,12 Additional prespecified analyses from these trials have provided important 91 
insights regarding which subjects are most likely to benefit from these novel therapies. 92 
This consideration is important due to ongoing debates around the cost-effectiveness of 93 
these agents.13 In this review, we will discuss the evidence supporting a personalized 94 
approach to the use of PCSK9-mAbs, outline areas of uncertainty, and what the future 95 





Cardiovascular Outcome Trials 100 
Both alirocumab and evolocumab have been evaluated in large, multi-center, 101 
randomized controlled trials that evaluated their effects on CV events and other key CV 102 
endpoints. An overview of the trials’ design and key findings is important given subsequent 103 
analyses of these data have provided significant guidance regarding which patients benefit 104 
most from PCSK9-mAbs (Table 1). 105 
The Further Cardiovascular Subjects with Elevated Risk (FOURIER) trial11 106 
evaluated the safety and efficacy of evolocumab in 27,564 subjects with stable ASCVD, 107 
defined as a history of MI, ischemic stroke, or symptomatic peripheral artery disease 108 
(PAD), already taking optimized statin therapy (at least atorvastatin 20 mg or equivalent) 109 
with a LDL-C ≥70 mg/dL or non-high-density lipoprotein cholesterol (non-HDL-C) ≥100 110 
mg/dL. The primary outcome was a composite of major adverse cardiovascular events 111 
(MACE), including CV death, MI, fatal or stroke, hospitalization for unstable angina, or 112 
coronary revascularization. The incidence of the primary outcome was significantly lower in 113 
subjects randomized to evolocumab (9.8%) compared to placebo (11.3%) (HR: 0.85; 95% 114 
CI, 0.79-0.92) with a number needed to treat (NNT) of 74. Evolocumab was also 115 
associated with reduction in the key secondary outcomes with significant reductions in MI 116 
(HR: 0.73; 95% CI, 0.65-0.82), stroke (HR: 0.79; 95% CI, 0.66-0.95), and coronary 117 
revascularization (HR: 0.78; 95% CI, 0.71-0.86). Injection-site reactions (2.1%) vs placebo 118 
(1.6%) were the only nominally significant adverse event in this trial (P<0.001). 119 
The Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome 120 
(ODYSSEY-OUTCOMES) trial12 evaluated alirocumab in 18,924 subjects with recent (1 to 121 
12 months) acute coronary syndrome (ACS) prior to enrollment on background high-122 
intensity statin therapy with an LDL-C ≥70 mg/dL, non-HDL-C ≥100 mg/dL, or 123 
apolipoprotein B (apoB) ≥ 80 mg/dL. The primary outcome was a composite of death from 124 
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coronary heart disease, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina 125 
requiring hospitalization. The incidence of the primary outcome was significantly lower in 126 
subjects randomized to alirocumab (9.5%) compared to placebo (11.1%) (HR: 0.85; 95% 127 
CI, 0.78-0.93) with an NNT of 63. Key secondary outcomes in favor of alirocumab versus 128 
placebo included any coronary heart disease event (death from coronary heart disease, 129 
nonfatal MI, unstable angina requiring hospitalization, and ischemia-driven coronary 130 
revascularization procedure) (HR: 0.88; 95% CI, 0.81-0.95), major coronary heart disease 131 
event (coronary heart disease and nonfatal MI) (HR: 0.88; 95% CI, 0.80-0.96), any CV 132 
event (death from CV causes, nonfatal MI, unstable angina requiring hospitalization, 133 
ischemia-driven coronary revascularization procedure, or nonfatal ischemic stroke) (HR: 134 
0.87; 95% CI, 0.81-0.94), and composite of death from any cause, nonfatal MI, or nonfatal 135 
ischemic stroke (HR: 0.86; 95% CI, 0.79-0.93). Injection-site reactions occurred more 136 
frequently in alirocumab-treated subjects (3.8%) compared to placebo (2.1%) (P<0.001).  137 
 138 
Evidence Supporting the Use of PCSK9-mAbs in Select Populations 139 
Multiple prespecified analyses of FOUREIR and ODYSSEY-OUTCOMES have 140 
provided important insights as to the specific populations and factors that clinicians may 141 
consider when identifying those most likely to benefit from alirocumab or evolocumab. 142 
These data also informed recent clinical practice guidelines and scientific statements, and 143 
reshaped the conversation around the cost-effectiveness of these therapies. 144 
 145 
Polyvascular disease 146 
It is important to note that ASCVD includes a broad range of vascular diseases, 147 
including significant atherosclerosis in the coronary, cerebrovascular, and/or peripheral 148 
arterial territories.1 A higher degree of atherosclerotic burden may be expected to impart 149 
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an increased risk of future ASCVD events. Thus, analysis of the benefits of PCSK9-mAbs 150 
in subjects with polyvascular ASCVD may be useful to determine which subjects are at 151 
highest risk and most likely to benefit from PCSK9-mAbs. While the primary endpoints of 152 
both FOURIER and ODYSSEY-OUTCOMES focused primarily on coronary and 153 
cerebrovascular events, subjects with pre-existing peripheral arterial disease (PAD) were 154 
included in FOURIER and a subset of subjects had baseline PAD in ODYSSEY-155 
OUTCOMES.  156 
Among the FOURIER study population, 13.2% of subjects had PAD at baseline and 157 
the majority (58.7%) of these subjects had a previous MI or stroke, in addition to PAD.11 158 
Subjects with PAD at baseline were more likely to demonstrate renal insufficiency, 159 
diabetes mellitus (DM), and smoke at baseline. In a post-hoc analysis14 of the FOURIER 160 
trial evaluating the efficacy of evolocumab by PAD at baseline, evolocumab significantly 161 
reduced the risk of the primary endpoint in both groups (PAD and no PAD) compared to 162 
placebo. Both the relative risk reduction (RRR) and absolute risk reduction (ARR) were 163 
lower in patients with PAD treated with evolocumab versus placebo (RRR=21%: 164 
ARR=3.5%) compared to subjects without PVD (RRR=14%; ARR=1.6%). The secondary 165 
composite endpoint of CV death, MI, or stroke occurred less frequently in subjects with 166 
PAD receiving evolocumab (9.5%) vs placebo (13%). Furthermore, major adverse limb 167 
events (MALE), including acute limb ischemia, urgent peripheral revascularization, and 168 
major amputations, were also assessed in the post-hoc analysis. Overall MALE rates were 169 
low (<1% in the entire study population) yet were lower among subjects receiving 170 
evolocumab compared to placebo in the overall study cohort (0.27% vs 0.45%; HR: 0.58; 171 
95% CI, 0.38-0.88). In subjects with PAD, MALE occurred at a higher frequency (1.5% 172 
evolocumab vs 2.4% placebo) and evolocumab was associated with lower risk of MALE 173 
(HR: 0.63; 95% CI, 0.39-1.03). Given that MALE was higher among subjects with PAD at 174 
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baseline, these subjects are at higher risk of ASCVD as well as MALE and seemed to 175 
benefit most from further LDL-C lowering with evolocumab.  176 
A prespecified analysis of ODYSSEY-OUTCOMES assessed risk of MACE by 177 
presence of mono- or poly-vascular disease.15 Monovascular disease was defined as 178 
coronary artery disease (CAD), while polyvascular disease was defined as ASCVD in two 179 
vascular areas (coronary plus cerebrovascular or peripheral arterial) or all three ASCVD 180 
sites (coronary, cerebrovascular, and peripheral arterial disease) among the 18,924 181 
subjects in the ODYSSEY-OUTCOMES trial. Overall, 91.8% of study subjects exhibited 182 
monovascular ASCVD, 7.4% exhibited polyvascular disease of two vascular sites, and 183 
0.8% manifested polyvascular disease in all three major vascular distributions. Notably, 184 
subjects with ASCVD in three sites were older, had lower rates of high-intensity statin use, 185 
exhibited greater LDL-C and Lp(a) levels at baseline, and were more likely to smoke. 186 
Similar to the results of the overall study population, alirocumab was associated with lower 187 
rates of the primary endpoint compared to placebo in those with monovascular disease 188 
(HR: 0.85; 95% CI, 0.77-0.93) and an ARR of 1.4% between treatment groups.  189 
Rates of the primary endpoint were higher in subjects with atherosclerosis at two 190 
sites (coronary and either cerebrovascular or peripheral arterial) than subjects with 191 
monovascular disease.15 However, there was no statistically significant reduction with 192 
evolocumab among subjects with CAD and PAD (HR: 0.93; 95% CI, 0.67-1.30) or those 193 
with CAD and cerebrovascular disease (HR: 0.87; 95% CI, 0.63-1.19). The ARR 194 
associated with alirocumab among subjects with CAD and evidence of vascular disease at 195 
an additional site was 1.9%. Subjects with vascular disease at all three sites (CAD, 196 
cerebrovascular, and PAD), had the highest rates of MACE and alirocumab was 197 
associated with a lower rate of MACE (26.8%) compared to placebo (39.7%) despite a 198 
non-significant reduction in the primary outcome (HR: 0.64; 95% CI, 0.35-1.12). The ARR 199 
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(13%) was greatest among this group of subjects with diffuse ASCVD and the NNT was 8. 200 
Similarly, all-cause mortality was significantly reduced among this group of subjects with 201 
polyvascular disease treated with alirocumab (5.6%) vs placebo (21.8), (HR: 0.23; 95% CI, 202 
0.08-0.68).  203 
  204 
Previous Myocardial Infarction  205 
A majority of subjects (81%) met FOURIER inclusion criteria by previous MI, with a 206 
median 3.4 years from most recent MI.11 A prespecified analysis of FOURIER sought to 207 
evaluate whether evolocumab would produce a greater ASCVD risk reduction among 208 
subjects considered at elevated risk.16 As such, subjects were stratified by time since most 209 
recent MI, number of previous MI events, as well as presence of residual multivessel CAD 210 
from the larger FOURIER study. Subjects with two or more previous MIs, multivessel CAD, 211 
or an MI within the previous two years exhibited higher rates of the primary MACE 212 
endpoint compared to those with one previous MI, no multivessel CAD, or an MI occurring 213 
more than 2 years ago. Each high-risk sub-group, except recent MI, were more likely to be 214 
male and had higher rates of PAD and hypertension. All three high-risk groups were more 215 
frequently prescribed high-intensity statin. For each high-risk subgroup, evolocumab was 216 
associated with an RRR of 18 to 21% and an ARR between 3.4% and 3.7% across the 217 
high-risk groups compared to placebo. From this analysis, subjects with recent MI, multiple 218 
MI events, or residual multivessel CAD represent a group with elevated ASCVD risk 219 
despite statin treatment who appear to derive greater absolute risk reduction with the 220 
addition of a PCSK-mAb. 221 
 222 
Coronary Artery Bypass Graft Surgery 223 
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A prespecified analysis of ODYSSEY OUTCOMES sought to determine the benefit 224 
of alirocumab stratified by prior CABG.17 For this analysis, three subgroups were identified; 225 
no previous CABG (89.3%), CABG following the index ACS event (5.4%), and CABG prior 226 
to index event (5.3%). Those with prior CABG were older, more likely to be male, had 227 
lower utilization of high-intensity statins, and had higher baseline LDL-C, apoB, and Lp(a) 228 
levels compared to the other CABG sub-groups. Across all three CABG sub-groups, 229 
alirocumab was associated with lower rates of the primary composite MACE outcome 230 
compared to placebo but appeared to have the greatest risk reduction among those with 231 
prior CABG (24.5% versus 30.9%, HR: 0.77; 95% CI, 0.61-0.98). Additionally, rates of CV 232 
death were lower among subjects treated with alirocumab (5.6%) compared to placebo 233 
(9.2%), with an ARR of 3.6% (HR: 0.61; 95% CI, 0.38-0.97).  234 
 235 
Diabetes mellitus  236 
A prespecified analysis of ODYSSEY-OUTCOMES assessed the efficacy of 237 
evolocumab according to DM status at baseline.18 Among the total study population, 238 
28.8% of subjects had confirmed DM at baseline and 43.6% had prediabetes. Achieved 239 
LDL-C values were similar among subjects receiving placebo or alirocumab across all 240 
three sub-groups. The primary endpoint occurred at higher rates in subjects with DM and 241 
prediabetes compared to normal glucose in both the placebo and alirocumab groups. 242 
Among subjects with normal glucose, the primary endpoint occurred in 7.3% in alirocumab 243 
and 8.5% in placebo groups (HR: 0.85; 95% CI, 0.70-1.03). In the subgroup of subjects 244 
with prediabetes, the primary endpoint occurred in 8.0% and 9.2% of subjects in the 245 
alirocumab and placebo groups, respectively (HR: 0.86; 95% CI, 0.74-1.00). Note, both the 246 
normal glucose and prediabetes subjects treated with alirocumab experienced an ARR of 247 
1.2% compared to placebo. In the subgroup of subjects with DM, event rates occurred in 248 
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14.1% and 16.4% of subjects in the alirocumab and placebo groups, respectively (HR: 249 
0.84; 95% CI, 0.74-0.97). It is noteworthy that the corresponding ARR of 2.3% was nearly 250 
double that of normal or prediabetes subgroups.  251 
Risk of new-onset DM is a concern associated with statin therapy, although likely a 252 
greater risk to those with pre-existing risk factors for developing DM (e.g., 253 
overweight/obese, family history).19 A prespecified safety analysis of the ODYSSEY-254 
OUTCOMES trial evaluated the risk of developing new-onset DM associated with 255 
alirocumab.18 In subjects with normal glucose status at baseline, 3.0% of subjects treated 256 
with alirocumab and 2.4% of subjects treated with placebo developed DM. In the 257 
prediabetes subgroup, the rates of new-onset DM were 13.8% for alirocumab and 15.3% 258 
for placebo. From this subgroup analysis, it appears that subjects with DM are at increased 259 
risk for subsequent ASCVD following an ACS event, with a greater risk reduction when 260 
treated with alirocumab. For subjects at risk of developing DM, alirocumab does not 261 
appear to increase the risk of new-onset DM. 262 
An analysis from the FOURIER trial reported similar findings in a prespecified 263 
analysis of DM status.20 Among the study subjects, 40% had DM and the rest were 264 
categorized as non-DM, although a majority of these subjects (62.6%) met criteria for 265 
prediabetes. Risk of the primary composite MACE endpoint was lower among subjects 266 
with DM treated with evolocumab (HR: 0.83; 95% CI, 0.75-0.93) and in those without DM 267 
(HR: 0.87; 95% CI, 0.79-0.96), similar to the findings of the ODYSSEY-OUTCOMES sub-268 
group analysis.18 Additionally, the ARR was greater among subjects with DM compared to 269 
those without DM (2.7% vs 1.6%, respectively). The risk of new-onset DM was not 270 
increased with evolocumab among subjects without DM at baseline, including those with 271 
prediabetes.  272 
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Although both trials11,12 were of relatively short duration (less than 3 years), a large 273 
proportion of subjects with DM at baseline were included in both trials. Results of these 274 
subgroup analyses suggest PCSK9-mAbs result in a greater risk reduction in subjects with 275 
DM without increasing the risk of new-onset DM, even in subjects with prediabetes. These 276 
results contrast to Mendelian randomization studies that suggest that genetic variants in 277 
PCSK9, used as a surrogate for therapeutic PCSK9-mAbs, were associated with 278 
increased risk of DM.21,22 It is important to note that both of CV outcome trials were of 279 
relatively short duration and longer follow-up of patients on PCSK9-mAbs will be critical to 280 
assess their impact on the future development of DM.  281 
 282 
Chronic Kidney Disease    283 
Similar to DM, coronary heart disease is the leading cause of death in individuals 284 
with chronic kidney disease (CKD).23 Benefits of evolocumab on MACE by CKD status 285 
was assessed in a post-hoc analysis of the FOURIER trial.24 Information on kidney 286 
function was available for nearly all subjects (99.96%) and subjects were categorized by 287 
eGFR calculated by CKD-EPI equation. A majority of subjects (54.6%) had stage 2 CKD, 288 
16.1% had stage 3 CKD or lower, and 29.3% had preserved renal function. Subjects with 289 
at least stage 3 CKD were more likely to have hypertension and DM, higher baseline TG 290 
and Lp(a) values, more likely to be treated with a renin-angiotensin-aldosterone inhibitor, 291 
but less likely to be receiving antiplatelet agents. Stage 3 CKD or higher was associated 292 
with an increased risk of MACE (HR: 1.36; 95% CI, 1.20-1.54) compared to normal kidney 293 
function, while no increased risk was seen in subjects with stage 2 CKD compared to 294 
preserved renal function.  295 
Primary event rates by CKD status demonstrated that for each subgroup, treatment 296 
with evolocumab was associated with a lower risk of the primary endpoint at 30 months.24 297 
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For subjects with at least stage 3 CKD, a primary endpoint occurred in 14.6% and 16.1% 298 
of subjects treated with evolocumab and placebo, respectively (HR: 0.89; 95% CI, 0.76-299 
1.05). Subjects with preserved renal function treated with evolocumab also experienced 300 
fewer primary events (10.0%) versus placebo (12.2%) (HR: 0.82; 95% CI, 0.71-0.94). 301 
Subjects with preserved function were found to have the greatest ARR (2.2%) with 302 
evolocumab, while those with at least stage 3 CKD had the lowest ARR (1.5%) for the 303 
primary endpoint; however, greater ARR was seen in patients with at least stage 3 CKD for 304 
the key composite secondary endpoint (CV death, MI, or stroke) compared to preserved 305 
renal function. No significant differences in changes to renal function were noted between 306 
the placebo group according to baseline kidney function. Although associated with a lower 307 
ARR for the primary outcome, subjects with worse renal function had the highest rates of 308 
MACE and appeared to benefit most from evolocumab when assessed for the key 309 
secondary endpoint of CV death, MI, or stroke. Given the apparent renal safety of 310 
evolocumab, those with previous ASCVD and additional risk factors, such as CKD, are 311 
likely to derive larger risk reductions than subjects without additional risk factors.   312 
 313 
Elevated Lp(a) Levels 314 
Lipoprotein(a) is an LDL-like particle synthesized by the liver that contains an  315 
apoB molecule and apolipoprotein (a) [apo(a)].25 Elevated Lp(a) levels are strongly 316 
associated with an increased risk of ASCVD and calcific aortic stenosis.26,27 A meta-317 
analysis of 27 randomized controlled trials found PCSK9-mAbs reduce Lp(a) levels by 318 
21.9% (95% CI, -24.3 to -19.5).28 However, it remains unclear whether reduction in Lp(a) 319 
with drug therapy reduces CV event rates as this has yet to be evaluated in a prospective, 320 
randomized controlled trial.  321 
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In a prespecified analysis of the FOURIER trial, investigators sought to assess the 322 
relationship between evolocumab, Lp(a) levels, and CV events.29 The median Lp(a) at 323 
baseline was 37 nmol/L (IQR 13-165), while the quartile with the highest baseline Lp(a) 324 
had a mean value of 216.0 nmol/L. By week 48, Lp(a) had been reduced by 26.9% with 325 
evolocumab, with greater absolute reductions seen in the highest Lp(a) quartile. In 326 
subjects with baseline Lp(a) values at or below the median, evolocumab was associated 327 
with a non-significant reduction of the composite primary endpoint (HR: 0.93; 95% CI, 328 
0.80-1.08). In subjects with Lp(a) levels above the median baseline value, event rates 329 
were significantly lower with evolocumab compared to placebo (HR: 0.77; 95% CI, 0.67-330 
0.88). Stratifying subjects by Lp(a) also identified a significant reduction in the composite 331 
CV outcome among subjects with baseline Lp(a) above 120 nmol/L (HR: 0.75; 95% CI, 332 
0.64-0.88), while the risk reduction was less in subjects with baseline Lp(a) below 120 333 
nmol/L (HR: 0.89; 95% CI, 0.79-1.01). An exploratory analysis also assessed the 334 
relationship between achieved LDL-C and Lp(a) and suggested greater risk reduction in 335 
subjects achieving both LDL-C and Lp(a) levels below the median value. In total, it 336 
appears that subjects with ASCVD and elevated Lp(a) are at higher risk for subsequent CV 337 
events and may derive greater risk reduction with PCSK9-mAbs. Whether lowering Lp(a) 338 
reduces ASCVD risk remains unknown, but this exploratory analysis suggests that 339 
achieving low levels of both Lp(a) and LDL-C may offer greater CV risk reduction. 340 
 341 
Clinical Practice Guidelines and Scientific Statements 342 
 In light of recent clinical outcome data from FOURIER and ODYSSEY-343 
OUTCOMES, clinical practice guidelines and scientific statements from various 344 
professional organizations were updated in 2018 and 2019. It is clear from these 345 
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recommendations that clinicians should individualize treatment decisions to ensure 346 
PCSK9-mAb use is targeted at patients most likely to benefit. 347 
 348 
2018 American College of Cardiology/American Heart Association/Multi-society 349 
Cholesterol Guideline 350 
This guideline stratified subjects with clinical ASCVD into two groups: 1) not at very-351 
high risk and 2) at very high risk (Table 2).4 By definition, very-high risk includes patients 352 
with clinical ASCVD with multiple major ASCVD events or who have had one major 353 
ASCVD event and have other high-risk conditions. This approach embodies the concept of 354 
individualizing the use of PCSK9-mAbs to those at the highest risk who are most likely to 355 
benefit.  356 
The guideline recommends adding ezetimibe to maximally tolerated statin therapy 357 
for patients at very high-risk with an LDL-C threshold of 70 mg/dL or greater before 358 
considering a PCSK9-mAb.4 This decision was based on several factors. Cost-359 
effectiveness was a major consideration as ezetimibe is an oral, once-daily tablet that is 360 
available as a generic, while PCSK9 inhibitors are fully human mAbs with an average 361 
wholesale price of approximately $14,000/year at the time the guideline was being 362 
developed. Thus, for the first time, the writing committee added a value statement 363 
indicating that PCSK9-mAbs were not deemed cost-effective in patients with ASCVD or 364 
familial hypercholesterolemia (FH). Additionally, ezetimibe is administered orally, which 365 
may be preferred by many patients and observational data suggests that upwards of 58% 366 
of patients receiving a high-intensity statin plus ezetimibe will achieve an LDL-C below 70 367 
mg/dL.30 Therefore, from a practical perspective, a trial of ezetimibe is reasonable before 368 
considering a PCSK9-mAb and is sometimes required by third party payers before a prior 369 
authorization for a PCSK9-mAb will be approved. 370 
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As for other groups, including patients with ASCVD who are not at very high-risk 371 
and primary prevention groups with or without DM, there are no recommendations to 372 
consider PCSK9-mAbs in any case. The use of PCSK9-mAbs is recommended as an 373 
option for patients with severe hypercholesterolemia (LDL-C >190 mg/dL) but only after 374 
receiving maximally tolerated statin and ezetimibe. The value of PCSK9-mAbs for patients 375 
with FH was deemed uncertain at mid-2018 prices. 376 
 377 
2019 Consensus Statement from the National Lipid Association 378 
Following release of the 2018 ACC/AHA/Multi-Society Cholesterol Guideline, the 379 
average wholesale price for alirocumab and evolocumab was reduced by 60%.31 The 380 
authors of this statement carefully reviewed subgroup analyses of FOURIER and 381 
ODYSSEY-OUTCOMES to identify groups of patients where alirocumab and evolocumab 382 
would be of reasonable value based on the lower price.31 This evaluation was performed 383 
by considering the net benefit from LDL-C lowering according to the ARR and NNT based 384 
on estimates for LDL-C reductions of 20%, 50%, and 65% with PCSK9-mAbs. Accordingly, 385 
the authors determined that PCSK9-mAbs were of reasonable (<US$100,000 per quality 386 
adjusted life year [QALY]) or high (<US$50,000 per QALY) value in select higher risk 387 
groups according to 2019 prices (Table 2). Additionally, the authors determined that the 5-388 
year NNT ranged from 21 to 28 among these high-risk groups, further supporting the value 389 
of alirocumab and evolocumab in these groups. 390 
 391 
2019 European Society of Cardiology/European Atherosclerosis Society Guidelines for the 392 
Management of Dyslipidemias 393 
 Similar to US Guidelines, the European Dyslipidemia Guidelines continue to support 394 
the initial use of maximally tolerated statin and ezetimibe before considering a PCSK9-395 
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mAb.32 Similar to the US Guideline, PCSK9-mAbs are recommended in subjects who are 396 
at very-high risk, although this is defined slightly differently (Table 2). The very-high risk 397 
category not only includes patients with established ASCVD, but also those who have DM 398 
with target organ damage, at least three risk factors, or early diagnosis; as well as subjects 399 
with severe CKD, a calculated SCORE >10% for 10-year risk of fatal CV disease, and 400 
subjects with FH and additional risk factors. Whereas the US Guidelines recommend 401 
PCSK9-mAbs primarily for those with established ASCVD, the European Guidelines allow 402 
consideration for their use in very-high risk primary prevention patients. One factor that 403 
may have informed the decision to more broadly recommend PCSK9-mAbs was the need 404 
to have more potent LDL-C lowering to achieve the lower LDL-C goal (<55 mg/dL) that the 405 
European Guidelines committee established for very-high risk secondary and primary 406 
prevention subjects and very-high risk subjects with DM or FH. 407 
 Issues related to cost-effectiveness are discussed in detail in the European 408 
Guideline.32 The cost-effectiveness of generically available statins and ezetimibe is 409 
reaffirmed, while the cost-effectiveness of PCSK9-mAbs is linked to a variety of high-risk 410 
patient groups based on lower prices. Importantly, the guideline notes the evidence gaps 411 
for determining the cost-effectiveness of lipid-lowering treatments, including the need for 412 
more precise risk estimation scores to better target intervention needs and longer-term 413 
studies that would help provide more precise cost-effectiveness estimates. 414 
 415 
Remaining Questions and Ongoing Clinical Trials 416 
Long-Term Safety of PCSK9-mAbs 417 
There is limited long-term safety data with PCSK9-mAbs as FOURIER and 418 
ODYSSEY-OUTCOMES were limited to a median 2.2 and 2.8 years of follow-up, 419 
respectively. The Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER-1) 420 
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trial was initiated in 2011 to help address this concern.33 Subjects enrolled in OSLER-1 421 
were randomized to standard of care or evolocumab 420 mg monthly for one year, then 422 
subjects could opt-in to the all-evolocumab period and receive evolocumab for four 423 
additional years. Of the 1,324 subjects originally enrolled in OSLER-1, long-term (up to 5 424 
years) safety results were available for 1,255 of these subjects. The mean ± standard 425 
deviation (SD) for age was 57 ± 12 years and 53% were female. A consistent LDL-C 426 
reduction of approximately 56% was maintained over the study period. Importantly, there 427 
were no significant differences between groups for adverse event rates and no neutralizing 428 
antibodies were detected with evolocumab use. 429 
Currently, a multicenter, open-label extension study of the FOURIER trial 430 
(clinicaltrials.gov, NCT03080935) is ongoing to provide extended long-term safety data in 431 
subjects who completed the FOURIER trial. Subjects will have laboratory assessments at 432 
day 1, week 12, and every 6 months thereafter. This study will enroll 1600 subjects and 433 
continue for approximately 5 years. The primary endpoint is incidence of adverse events. 434 
The anticipated study completion date is 2022 and it will provide valuable data regarding 435 
the long-term safety of evolocumab. 436 
 437 
PCSK9-mAb Use in the Acute Setting 438 
Early initiation of high-intensity statin therapy during the acute MI phase 439 
demonstrated significant reductions in CV events and mortality.34 However, the addition of 440 
a PCSK9-mAb to background statin therapy during this acute MI phase has only recently 441 
been explored.  442 
Trankle, et al.35 randomized 20 subjects with type 1 non-ST-elevation myocardial 443 
infarction (NSTEMI) and an LDL-C >70 mg/dL despite high-intensity statin therapy to either 444 
a single dose of alirocumab 150 mg or placebo within 24 hours of presentation. The 445 
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primary endpoint was change in LDL-C at 14 days. The median baseline LDL-C was 98 446 
mg/dL and 91 mg/dL in the placebo and alirocumab groups, respectively. At 72 hours, 447 
subjects receiving placebo experienced a very modest reduction in LDL-C to 94 mg/dL, 448 
while those receiving alirocumab achieved an LDL-C level of 73 mg/dL (P<0.02). At 14 449 
days, the LDL-C in the placebo group was 90 mg/dL, while the LDL-C in the alirocumab 450 
group was further reduced to 28 mg/dL (P<0.001). Secondary endpoints included changes 451 
in high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), interleukin-10 (IL-10), 452 
and tumor necrosis factor ɑ (TNF-ɑ), but there were no significant differences for between-453 
group changes. 454 
Koskinas, et al.36 published a larger trial, Evolocumab for Early Reduction of LDL-455 
cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS), involving 308 456 
subjects hospitalized for non-ST-elevation ACS with symptom onset <72 hours or ST-457 
elevation myocardial infarction with symptom onset <24 hours who had elevated LDL-C, 458 
regardless of background lipid-lowering therapy. Participants were randomized to either 459 
evolocumab 420 mg or matching placebo, along with atorvastatin 40 mg. Interestingly, 460 
78.2% of subjects were not receiving statin therapy at baseline. Those randomized to 461 
evolocumab had a 77.1% reduction in LDL-C by week eight and 95.7% achieved an LDL-C 462 
<70 mg/dL, while the placebo group achieved only a 35.4% reduction in LDL-C and only 463 
37.6% achieved an LDL-C <70 mg/dL. Similar to the findings reported by Trankle, et al.35, 464 
the change in hsCRP and other inflammatory markers were not significantly different 465 
between groups. Adverse event rates were similar between the two groups. 466 
While both studies demonstrated the feasibility of initiating a PCSK9-mAb during the 467 
acute MI phase, it remains unknown if this early initiation would lead to a reduction in CV 468 
events. The ODYSSEY-OUTCOMES trial12 enrolled post-ACS subjects 1 to 12 months 469 
from their index event, but only one-third of the participants were randomized less than two 470 
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months from the index event. However, the greatest relative risk reduction (HR 0.83; 95% 471 
CI, 0.71 to 0.96) was observed in this group, suggesting there may be greater benefit with 472 
earlier initiation of PCSK9-mAbs.   473 
 474 
PCSK9-mAb Use in Subjects Without Prior MI or Stroke 475 
 While there is clear evidence supporting the use of alirocumab and evolocumab in 476 
secondary and post-ACS populations, it is unknown if these agents can reduce CV events 477 
in subjects without prior MI or stroke. The Effect of Evolocumab in Subjects at High 478 
Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VESALIUS-CV) trial is a 479 
randomized, double-blind, placebo-controlled, multicenter study seeking to answer this 480 
question (clinicaltrials.gov, NCT03872401). The trial has a co-primary outcome of 3-point 481 
(coronary heart disease death, MI, or ischemic stroke) and 4-point (coronary heart disease 482 
death, MI, or ischemic stroke, any ischemia-driven arterial stroke) MACE. Eligible subjects 483 
include adults aged 50 to 75 years with an LDL-C >100 mg/dL or non-HDL-C >130 mg/dL 484 
at screening, after at least 4 weeks of optimized lipid-lowering therapy, evidence of 485 
significant CAD, cerebrovascular disease, PAD, or DM, and at least one additional high-486 
risk feature. Importantly, those with a prior MI, stroke, or CABG will be excluded. 487 
Participants will be randomized to placebo or evolocumab 140 mg b-weekly for a minimum 488 
of four years. The anticipated study completion date is 2024. If the use of evolocumab 489 
improves cardiovascular outcomes in this population, it may dramatically increase the 490 
number of patients eligible for PCSK9-mAb therapy. 491 
 492 
Silencing PCSK9 with Inclisiran  493 
 While initial approaches to modulating PCSK9 have focused on the use of mAbs to 494 
inhibit the function of PCSK9, inclisiran targets PCSK9 synthesis via small interfering RNA 495 
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(siRNA) (Figure 1). Inclisiran is a long acting synthetic siRNA conjugated to traiantennary 496 
N-acetylgalactosamine carbohydrates (GalNAC) which bind hepatocyte expressed 497 
asialoglycoprotein receptors.37 Once inside the hepatocyte, inclisiran targets specifically, 498 
and hence, silences the PCSK9 messenger RNA (mRNA) by preventing its translation. As 499 
a result, PCSK9 synthesis is dramatically reduced. Since plasma concentration of PCSK9 500 
is markedly decreased, LDL receptors are maximally expressed, resulting in significant 501 
LDL-C reduction. One advantage of inclisiran compared to PCSK9-mAbs is the potential 502 
for a longer duration of action requiring less frequent administration.38 503 
 In the phase 2 Trial to Evaluate the Effect of ALN-PCSSC (i.e., inclisiran) Treatment 504 
on LDL-C (ORION-1)39, subjects with an LDL-C >70 mg/dL (presence of clinical ASCVD) 505 
or LDL-C >100 mg/dL (absence of clinical ASCVD) on maximally tolerated statin were 506 
randomized to one of eight groups: single dose of inclisiran (200, 300, or 500 mg) or 507 
placebo, or two doses of inclisiran on day 1 and day 90 (100, 200, or 300 mg) or placebo. 508 
The primary endpoint was change in LDL-C from baseline to day 180, which ranged from 509 
27.9% to 41.9% (single dose) and 35.5% to 52.6% (two doses). These LDL-C reductions 510 
were statistically significant for all comparisons versus placebo (P<0.001). The greatest 511 
reduction in LDL-C was found with the two 300 mg doses of inclisiran as nearly 50% of 512 
these individuals achieved an LDL-C below 50 mg/dL at day 180. Adverse events with 513 
inclisiran included injection site reactions (5%), hepatic injury (rare), and development of 514 
antidrug antibodies (only one patient).  515 
The efficacy of inclisiran is highly durable as it reduces LDL-C by 54% when 516 
administered as 300 mg on day 1, 90, and then every six months.40 Additionally, in the 517 
ORION-11 trial (clinicaltrials.gov, NCT03400800), an exploratory composite endpoint of 518 
CV death, cardiac arrest, non-fatal MI, or stroke occurred in 63 patients (7.8 percent) in the 519 
inclisiran group compared to 83 patients (10.3 percent) in the placebo group.40 Thus, 520 
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despite differences in mechanism of action, it appears that inclisiran produces similar 521 
reductions in LDL-C as PCSK9-mAbs and may also produce similar reductions in major 522 
CV events. The ongoing ORION-4 trial (clinicaltrials.gov, NCT03705234) is evaluating the 523 
effect of inclisiran on CV outcomes and is expected to be completed in 2024.  524 
   525 
Conclusion 526 
In less than two decades since the discovery of PCSK9, there are two approved 527 
therapeutic agents that target plasma PCSK9 and significantly reduce LDL-C. Moreover, 528 
both PCSK9-mAbs demonstrated improvement in CV outcomes in randomized controlled 529 
trials. These trials also demonstrate that individuals at very-high risk of ASCVD events 530 
garner the greatest benefit with these therapies. The use of PCSK9-mABs appears most 531 
cost-effective in this high-risk population as well. It remains to be seen, however, if these 532 
therapies will be utilized in lower-risk patients or ever be considered for use as a 533 
monotherapy option. Ongoing safety extension trials may provide further evidence that 534 
maintaining very low levels of LDL-C via pharmacologic intervention is indeed safe and 535 
maximizes ASCVD risk reduction. New developments with novel approaches to 536 
antagonizing PCSK9, such as siRNA therapies, will only enhance our ability to sustain 537 
significant reductions in LDL-C levels with a lower medication burden and possibly 538 









1.  Roth GA, Johnson C, Abajobir A, et al. Global , Regional , and National Burden of 547 
Cardiovascular Diseases for 10 Causes , 1990 to 2015. J Am Coll Cardiol. 548 
2017;70(1):1-25. doi:10.1016/j.jacc.2017.04.052 549 
2.  Curtin SC. Trends in Cancer and Heart Disease Death Rates Among Adults Aged 550 
45-64: United States, 1999-2017. Natl Vital Stat Reports. 2019;68(5):1-9. 551 
3.  Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause 552 
atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and 553 
clinical studies. A consensus statement from the European Atherosclerosis Society 554 
Consensus Panel. Eur Heart J. 2017;0:1-14. doi:10.1093/eurheartj/ehx144 555 
4.  Grundy SM, Stone NJ, Bailey AL, et al. 2018 556 
AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA 557 
Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 558 
2019;73(24):e285-e350. doi:10.1016/j.jacc.2018.11.003 559 
5.  Dixon DL, Trankle C, Buckley L, et al. A review of PCSK9 inhibition and its effects 560 
beyond LDL receptors. J Clin Lipidol. 2016. doi:10.1016/j.jacl.2016.07.004 561 
6.  Zaid A, Roubtsova A, Essalmani R, et al. Proprotein convertase subtilisin/kexin type 562 
9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and 563 
critical role in mouse liver regeneration. Hepatology. 2008;48(2):646-654. 564 
doi:10.1002/hep.22354 565 
7.  Goldstein JL, Brown MS. History of Discovery : The LDL Receptor. Arterioscler 566 
Thromb. 2010;29(4):431-438. doi:10.1161/ATVBAHA.108.179564.History 567 
8.  Stein E, Wasserman S, Dias C, Scott R, Raal F. AMG-145. Anti-PCSK9 monoclonal 568 
antibody, Treatment of lipoprotein disorders. Drugs Fut. 2013;38(7):451-459. 569 
doi:10.1358/dof.2013.38.7.1981967 570 
 24 
9.  Kühnast S, Van Der Hoorn JWA, Pieterman EJ, et al. Alirocumab inhibits 571 
atherosclerosis, improves the plaque morphology, and enhances the effects of a 572 
statin. J Lipid Res. 2014;55(10):2103-2112. doi:10.1194/jlr.M051326 573 
10.  Zhang XL, Zhu QQ, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: A 574 
meta-analysis of 25 randomized, controlled trials. BMC Med. 2015;13(1). 575 
doi:10.1186/s12916-015-0358-8 576 
11.  Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in 577 
Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. 578 
doi:10.1056/NEJMoa1615664 579 
12.  Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes 580 
after Acute Coronary Syndrome. N Engl J Med. 2018:NEJMoa1801174. 581 
doi:10.1056/NEJMoa1801174 582 
13.  Weintraub WS, Gidding SS. PCSK9 Inhibitors : A Technology Worth Paying For ? 583 
Pharmacoeconomics. 2016;34(3):217-220. doi:10.1007/s40273-015-0355-y 584 
14.  Bonaca MP, Nault P, Giugliano RP, et al. Low-Density Lipoprotein Cholesterol 585 
Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery 586 
Disease: Insights from the FOURIER Trial (Further Cardiovascular Outcomes 587 
Research with PCSK9 Inhibition in Subjects with Elevated Risk). Circulation. 588 
2018;137(4):338-350. doi:10.1161/CIRCULATIONAHA.117.032235 589 
15.  Jukema JW, Szarek M, Zijlstra LE, et al. Alirocumab in Patients With Polyvascular 590 
Disease and Recent Acute Coronary Syndrome. J Am Coll Cardiol. 591 
2019;74(9):1167-1176. doi:10.1016/j.jacc.2019.03.013 592 
16.  Sabatine MS, De Ferrari GM, Giugliano RP, et al. Clinical benefit of evolocumab by 593 
severity and extent of coronary artery disease analysis from Fourier. Circulation. 594 
2018;138(8):756-766. doi:10.1161/CIRCULATIONAHA.118.034309 595 
 25 
17.  Goodman SG, Aylward PE, Szarek M, et al. Effects of Alirocumab on Cardiovascular 596 
Events After Coronary Bypass Surgery. J Am Coll Cardiol. 2019;74(9):1177-1186. 597 
doi:10.1016/j.jacc.2019.07.015 598 
18.  Ray KK, Colhoun HM, Szarek M, et al. Effects of alirocumab on cardiovascular and 599 
metabolic outcomes after acute coronary syndrome in patients with or without 600 
diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised 601 
controlled trial. Lancet Diabetes Endocrinol. 2019;7(8):618-628. doi:10.1016/S2213-602 
8587(19)30158-5 603 
19.  Sattar N, Preiss D, Murray HM. Statins and risk of incident diabetes: A collaborative 604 
meta-analysis of randomised statin trials. Rev Port Cardiol. 2010;29(6):1077-1078. 605 
doi:10.1016/S0140-6736(09)61965-6 606 
20.  Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the 607 
PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of 608 
evolocumab on glycaemia and risk of new-onset diabetes: A prespecified analysis of 609 
the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 610 
2017;8587(17):1-10. doi:10.1016/S2213-8587(17)30313-3 611 
21.  Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and 612 
risk of cardiovascular disease and diabetes. N Engl J Med. 2016;375(22):2144-2153. 613 
doi:10.1056/NEJMoa1604304 614 
22.  Schmidt AF, Swerdlow DI, Holmes M V., et al. PCSK9 genetic variants and risk of 615 
type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol. 616 
2017;5(2):97-105. doi:10.1016/S2213-8587(16)30396-5 617 
23.  Van Der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular 618 
filtration rate and higher albuminuria are associated with all-cause and 619 
cardiovascular mortality. A collaborative meta-analysis of high-risk population 620 
 26 
cohorts. Kidney Int. 2011;79(12):1341-1352. doi:10.1038/ki.2010.536 621 
24.  Charytan DM, Sabatine MS, Pedersen TR, et al. Efficacy and Safety of Evolocumab 622 
in Chronic Kidney Disease in the FOURIER Trial. J Am Coll Cardiol. 623 
2019;73(23):2961-2970. doi:10.1016/j.jacc.2019.03.513 624 
25.  Tsimikas S, Fazio S, Ferdinand KC, et al. NHLBI Working Group Recommendations 625 
to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and 626 
Aortic Stenosis. J Am Coll Cardiol. 2018;71(2):177-192. 627 
doi:10.1016/j.jacc.2017.11.014 628 
26.  Saeed A, Sun W, Agarwala A, et al. Lipoprotein(a) levels and risk of cardiovascular 629 
disease events in individuals with diabetes mellitus or prediabetes: The 630 
Atherosclerosis Risk in Communities study. Atherosclerosis. 2019;282(July 631 
2018):52-56. doi:10.1016/j.atherosclerosis.2018.12.022 632 
27.  Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and 633 
risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 634 
2014;63(5):470-477. doi:10.1016/j.jacc.2013.09.038 635 
28.  Cao YX, Liu HH, Li S, Li JJ. A Meta-Analysis of the Effect of PCSK9-Monoclonal 636 
Antibodies on Circulating Lipoprotein (a) Levels. Am J Cardiovasc Drugs. 637 
2019;19(1):87-97. doi:10.1007/s40256-018-0303-2 638 
29.  O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 Inhibition, and 639 
Cardiovascular Risk. Circulation. 2019;139(12):1483-1492. 640 
doi:10.1161/CIRCULATIONAHA.118.037184 641 
30.  Virani SS, Akeroyd JM, Nambi V, et al. Estimation of Eligibility for Proprotein 642 
Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the 643 
FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition 644 
in Subjects with Elevated Risk): Insights from the Department of Veterans Affairs. 645 
 27 
Circulation. 2017;135(25):2572-2574. doi:10.1161/CIRCULATIONAHA.117.028503 646 
31.  Robinson JG, Jayanna MB, Brown AS, et al. Enhancing the value of PCSK9 647 
monoclonal antibodies by identifying patients most likely to benefit. J Clin Lipidol. 648 
2019. doi:10.1016/j.jacl.2019.05.005 649 
32.  Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the 650 
management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur 651 
Heart J. 2019:1-78. doi:10.1093/eurheartj/ehz455 652 
33.  Koren MJ, Sabatine MS, Giugliano RP, et al. Long-Term Efficacy and Safety of 653 
Evolocumab in Patients With Hypercholesterolemia. J Am Coll Cardiol. 654 
2019;74(17):2132-2146. doi:10.1016/j.jacc.2019.08.1024 655 
34.  Cannon C, Braunwald E, McCabe C, et al. Intensive versus Moderate Lipid Lowering 656 
with Statins after Acute Coronary Syndromes. N Engl J Med. 2004;350(15):1495-657 
1504. 658 
35.  Trankle CR, Kadariya D, Ravindra K, et al. Alirocumab in Acute Myocardial 659 
Infarction: Results From the Virginia Commonwealth University Alirocumab 660 
Response Trial (VCU-AlirocRT). J Cardiovasc Pharmacol. 2019;74(3):266-269. 661 
doi:10.1097/FJC.0000000000000706 662 
36.  Koskinas KC, Windecker S, Pedrazzini G, et al. Evolocumab for Early Reduction of 663 
LDL-Cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS). J 664 
Am Coll Cardiol. 2019;74(20). doi:10.1016/j.jacc.2019.08.010 665 
37.  Wang N, Tall AR. A New Approach to PCSK9 Therapeutics. Circ Res. 666 
2017;10032(212):1063-1066. doi:10.1038/ng1161.2. 667 
38.  Nordestgaard BG, Nicholls SJ, Langsted A, Ray KK, Tybjærg-Hansen A. Advances 668 
in lipid-lowering therapy through gene-silencing technologies. Nat Rev Cardiol. 2018. 669 
doi:10.1038/nrcardio.2018.3 670 
 28 
39.  Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in Patients at High Cardiovascular 671 
Risk with Elevated LDL Cholesterol. N Engl J Med. 2017;376(15):1430-1440. 672 
doi:10.1056/NEJMoa1615758 673 
40.  Substantial LDL-C reductions with the siRNA, inclisiran: Results from ORION-11. 674 
European Society of Cardiology. https://www.escardio.org/Congresses-&-675 
Events/ESC-Congress/Congress-resources/Congress-news/substantial-ldlc-676 
reductions-with-the-sirna-inclisiran-results-from-orion11. Published 2019. Accessed 677 



















Figure 1. Approaches to Modulating PCSK9 696 
Compares the mechanism of action for PCSK9-mAb (A) and siRNA (B) approaches to 697 
modulating PCSK9. Both result in increased presence of LDL-R on the hepatocyte surface 698 
by either inhibiting the functionality of PCSK9 (A) or turning off PCSK9 synthesis (B). 699 
Abbreviations: LDL-P, low-density lipoprotein particle; LDL-R, low-density lipoprotein 700 
receptor; mAb, monoclonal antibody; PCSK9, proprotein convertase subtilisin/kexin type 9; 701 












































Table 1. Baseline Characteristics of PCSK9-mAb Cardiovascular Outcome Trials 
Characteristic FOURIER11 ODYSSEY-OUTCOMES12 
Intervention Evolocumab 140 mg SC every two weeks or 420 
mg SC every four weeks 
Alirocumab 75 mg SC every two weeks 
Dose-adjusted, per protocol, to maintain LDL-C 
levels between 25 and 50 mg/dL 
Median study duration, years 2.2  2.8  
Mean age, years 62.5  58.5  
White 85% 79% 
Female sex 25% 25% 
Hypertension 80% 65% 
Diabetes mellitus 36% 29% 
Prior myocardial infarction 81% *19% 
Prior stroke 19% 3.2% 
High-intensity statin 69% 100% 
Ezetimibe use 2.9% 5.3% 
LDL-C, mg/dL 92 92 
* All patients enrolled had an index acute coronary syndrome but only 19% had a prior myocardial infarction 
LDL-C, low-density lipoprotein cholesterol; SC, subcutaneous 
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Very-high risk ASCVD 
 Multiple major ASCVD 
events 
 Single ASCVD event with 
multiple high-risk conditions 
Extremely-high risk 
 ≥40% 10-year ASCVD risk  
 
Very-high risk 
 30-39% 10-year ASCVD risk 
 
High risk 
 20-29% 10-year ASCVD risk 
 cardiometabolic risk factors 
Very-high risk 
 ASCVD ± FH 
 FH with other major risk factor 
 Chronic kidney disease with 
eGFR <30 ml/min/1.73m2 
 DM and target organ damage, ≥3 
major risk factors, or duration of 
T1DM >20 years 
 10-year risk of fatal CVD ≥10% 
 
Use in Patients 
with Clinical 
ASCVD 
Very-high risk ASCVD and 
LDL-C ≥70 mg/dL on maximal 
statin PLUS ezetimibe. 
 
Using a PCSK9 inhibitor before 




Extremely-high risk and LDL-C 
≥70 mg/dL  
 
Very-high risk and LDL-C ≥ 100 
mg/dL on maximal statin ± 
ezetimibe  
 
High risk with LDL-C ≥130 mg/dL 
on maximal statin ± ezetimibe 
 
Very-high risk with LDL-C ≥ 55 




Use in Patients 
Without Clinical 
ASCVD 
HeFH and LDL-C ≥100 mg/dL 
on maximal statin PLUS 
ezetimibe.  
 
Baseline LDL-C ≥ 220 mg/dL 
and current LDL-C ≥130 mg/dL 
on maximal statin PLUS 
ezetimibe. 
 
High risk and LDL-C ≥ 130 mg/dL 
on maximal statin ± ezetimibe 
Very-high risk with LDL-C ≥ 55 
mg/dL on maximal statin PLUS 
ezetimibe 
ACC/AHA= American College of Cardiology/American Heart Association; ASCVD= atherosclerotic cardiovascular disease; CVD= 
cardiovascular disease; DM= diabetes mellitus; ESC/EAS= European Society of Cardiology/European Atherosclerosis Society; 
HeFH= heterozygous familial hypercholesterolemia; LDL-C= low-density lipoprotein cholesterol; NLA= National Lipid Association 
 
Table 2
